Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer 4 2015 performance Outlook 5 2015: Targets fully achieved Targets for 2015 FY 2015 Group sales growth1 Mid-single digit +5% Core EPS growth1 Ahead of sales growth2 +7% Further increase dividend in Swiss francs3 Dividend outlook CHF 8.10 (Payout ratio increased to 60% from 56%) 1 At constant exchange rates (CER); 2 Excluding sale of filgrastim rights in 2014; 3 2015 dividend as proposed by the Board of Directors 6 2015: Highlights Growth Sales • Group sales +5%1 driven by HER2 franchise (+19%), Avastin (+9%), Esbriet (n.m.), Actemra (+23%) and Professional Diagnostics (+8%) Profit • +7% Core EPS growth1,2 driven by strong underlying business Innovation Oncology • Cancer immunotherapy: Phase II lung (POPLAR, BIRCH), rolling filing initiated; Phase II bladder (IMvigor 210), filed in US; 9 NMEs in clinical development • Alecensa (alectinib): Approved in US, filed in EU • Cotellic (cobimetinib): Approved in US and EU Hematology • Venetoclax: Filing acceptance in R/R CLL including 17p del in US • Gazyva: Phase III (GADOLIN) in R/R iNHL, filed in US and EU • Emicizumab (ACE 910): Updated phase Ib, start of Phase III in inhibitors Neuroscience • Ocrelizumab: Phase III in RMS (OPERA I/II) and PPMS (ORATORIO) 1 At constant exchange rates (CER); 2 Excluding sale of filgrastim rights in 2014 7 2015: Strong sales growth in both divisions 2015 2014 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 37.3 36.7 2 5 Diagnostics Division 10.8 10.8 0 6 Roche Group 48.1 47.5 1 5 CER=Constant Exchange Rates 8 2015: Sales growth for fifth consecutive year 10% 8% 8% 7% 7% 6% 6% 6% 6% 6% 5% 5% 6% 4% 5% 4% 4% 4% 4% 4% 2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 15 All growth rates at Constant Exchange Rates (CER) 9 2015: Strong sales growth in all regions CHFbn 21 +5% +1% 18 15 +3% +7% 12 +2% Diagnostics +13% 9 +6% Pharma 6 +5% 0% +5% +4% 3 +6% 0 Japan International Europe US All growth rates are YoY at Constant Exchange Rates (CER) 10 Roche: Significantly advancing patient care Recognition for innovation 2013-present Breakthrough Therapy Year Molecule Venetoclax (AML) 11 Designations 2016 Venetoclax + Rituxan (R/R CLL) Actemra (Systemic sclerosis) Rank Company # Atezolizumab (NSCLC) 2015 1 Roche 11 Venetoclax (R/R CLL 17p del) 2 BMS 8 Emicizumab/ACE 910 (Hemophilia A) 3 Novartis 6 Esbriet (IPF) 2014 Lucentis (DR) 3 Merck 6 Atezolizumab (Bladder) 3 Pfizer 6 Alectinib (2L ALK+ NSCLC) 2013 4 GSK 5 Gazyva (1L CLL) Source: http://www.focr.org/breakthrough-therapies as at 21 January 2016; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non- 11 Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy 2015: Strong underlying Group Core operating profit & margin % of sales 37.7% 38.3% 37.2% 36.4% (+0.7%*) 35.6% +5% at CER (+7%*) CHFbn 17.5 17.9 17.2 17.6 15.1 2011 2012 2013 2014 2015 CER=Constant Exchange Rates; * Excluding sale of filgrastim rights in 2014 12 2015: Strong underlying Core EPS growth +4% at CER (+7%*) 13.49 14.27 14.29 13.49 CHF 12.30 2011 2012 2013 2014 2015 All growth rates at Constant Exchange Rates (CER); * Excluding sale of filgrastim rights in 2014 13 2015: Dividend and payout ratio further increased CHF Dividend payout ratio (%) 60.0 10 55.3 56.0 9 2015 payout ratio: 60.0% 54.5 54.7 8.10 8 51.6 48.6 7 44.8 6 38.8 34.5 5 31.9 4 3 2 1 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 Payout ratio calculated as dividend per share divided by Core earnings per share (diluted); 2015 dividend as proposed by the Board of Directors; 14 Note:1 compound For 1995, a annualspecial dividend growth was rate paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996 2015: Core EPS growth bridge +2.9% +6.6% one-time +5.3% filgrastim* +3.7% Core EPS Core EPS Sales Full Year 2015 Full Year 2015 figures as reported excl. filgrastim* All growth rates at Constant Exchange Rates (CER); * Excluding sale of filgrastim rights in 2014 15 2015 performance Outlook 16 2016 onwards: Significant launch activities Venetoclax R/R CLL including 17p del Cotellic + Zelboraf Emicizumab (ACE910) BRAFmut melanoma Hemophilia A Alecensa Lebrikizumab NMEs 2L ALK+ lung cancer Severe Asthma Atezolizumab Ocrelizumab Lampalizumab 2L+ lung and bladder cancer RMS/ PPMS Geographic atrophy 2016 2017 2018 Gazyva Perjeta + Herceptin Atezolizumab + abraxane Refractory iNHL (GADOLIN) eBC HER2+ (APHINITY) TNBC Gazyva Atezolizumab+Avastin+chemo ine ine 1L aNHL (GOYA) 1L NSCLC l Actemra Atezolizumab + Avastin extensions Giant cell arteritis 1L RCC Gazyva 1L iNHL (GALLIUM) Alecensa 1L ALK+ NSCLC Oncology/ FDA Breakthrough Neuroscience Ophthalmology Immunology hematology Therapy Designation Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed. 17 2016 outlook Group sales growth1 Low to mid-single digit Core EPS growth1 Ahead of sales growth Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 18 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals 19 2015 results Innovation Outlook 20 2015: Pharma sales Strong growth driven by all regions 2015 2014 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 37,331 36,696 2 5 United States 17,616 15,822 11 6 Europe 8,734 9,422 -7 4 Japan 3,224 3,301 -2 6 International 7,757 8,151 -5 5 CER=Constant Exchange Rates 21 2015: Pharma Division Core operating profit growth +8%* 2015 2015 vs. 2014 CHFm % sales CER growth Sales 37,331 100.0 5% Excl. filgrastim* Royalties & other op. inc. 2,119 5.7 -11% +10% Cost of sales -7,900 -21.2 7% Capacity increase in manufacturing M & D -6,066 -16.2 4% R & D -8,134 -21.8 4% G & A -1,295 -3.5 -17% Excl. filgrastim* Core operating profit 16,055 43.0 5% +8% 0% in CHF CER=Constant Exchange Rates; * Excluding sale of filgrastim rights in 2014 22 2015: Strong performance from oncology and immunology franchises Herceptin +10% Avastin +9% Perjeta +61% Esbriet n.m. MabThera/Rituxan +5% Actemra/RoActemra +23% Kadcyla +51% Xolair +25% Xeloda -31% Lucentis -15% US Tamiflu -28% Europe Japan Valcyte/Cymevene -45% International Pegasys -44% CHFm -600 -400 -200 0 200 400 600 Absolute amounts and growth rates at Constant Exchange Rates (CER) 23 2015: Oncology with +8% growth YoY CER growth Perjeta HER2 Herceptin +19% • Strong uptake of Perjeta and Kadcyla • Growth of Herceptin due to longer treatment Kadcyla • Growth driven mainly by cervical and ovarian Avastin +9% • International: Strong growth in all regions MabThera/ Rituxan +4% • US: Growth in iNHL maintenance (Oncology) • In-class competition Tarceva -7% • EU: Avastin + Tarceva filed in 1L EGFR+ NSCLC Xeloda -31% • Loss of exclusivity • Competitive pressure in US and EU Zelboraf -21% • Cotellic + Zelboraf approved in Q4 CHFbn 0 2 4 6 8 10 CER=Constant Exchange Rates; 2015 Oncology sales: CHF 23.7bn; CER growth +8% 24 HER2 franchise: Continued strong growth CHFm YoY CER growth HER2 franchise Q4 2015 2,500 +18% • Herceptin (+10%): Longer treatment +19% duration in combo with Perjeta 2,000 • Perjeta (+50%): Strong demand in 1L mBC +20% +10% • Kadcyla (+36%): Growth driven by EU 1,500 1,000 Outlook 2016 • Perjeta: Further increasing penetration and 500 neoadjuvant uptake • Kadcyla: Increasing penetration and new 0 countries Q4 12 Q4 13 Q4 14 Q4 15 • Ph III APHINITY data (adj. HER2+) expected Herceptin Perjeta Kadcyla CER=Constant Exchange Rates 25 Strong subcutaneous conversion rates for Herceptin and MabThera Check SC share of Herceptin sales in SC share of MabThera NHL launched countries* sales in launched countries* NHL sales 40% 35% 30% 30% 25% 20% 20% 15% 10% 10% Sales market share (%) market Sales